Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.
Also called NCT02253654
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 216 participants
- Sponsor
- Registry
-
NCT02253654
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT02253654. Randomized; triple masking; primary purpose treatment. Start 2015-04-01 (actual); primary completion 2016-04-27 (actual). Results posted on 2017-05-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
- Condition
- Renal Insufficiency, Chronic
- Condition
- Anemia
- Condition
- Renal Dialysis
- Condition
- Erythrocyte Transfusion
- Intervention (Drug)
- Epoetin alfa
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct02253654- Content hash
bd952552491c12660edf9955477dcbb063aa251c07ecac694f8c511194f81467